Does pallidal neuromodulation influence cognitive decline in Huntington’s disease?

Sanrey, Emily; Macioce, Valérie; González, Victoria; Cif, Laura; Cyprien, Fabienne; Seng, Emilie Chan; Coubes, Philippe; Poulen, Gaëtan

doi:10.1007/s00415-020-10206-w

Cited by 4 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heterogeneous results were obtained for UHDRS TMS: in one study, a statistically significant deterioration of UHDRS TMS was shown six months after DBS, but not at the final follow-up (median 3 years after DBS) [11]. In another study, statistically significant deterioration of UHDRS TMS was shown at the final follow-up (median 4 years after DBS) [12].…”

Section: Long-term Motor and Functional Outcomes Of Dbsmentioning

confidence: 97%

“…In one of the studies [10], only a 6-month follow-up was available, and in two others no standardised behavioural assessment was reported [11,12]. Finally, we decided to include and analyse one RCT and three open trials reporting any motor, functional, cognitive and behavioural data with at least a 6-month followup [9][10][11][12] (Fig. 1), even if this data was limited in terms of follow-up length, and not as extensive as expected.…”

Section: Paper Selectionmentioning

confidence: 99%

“…Patients undergoing DBS implantation in the analysed studies were in different disease stages, and disease stage was assessed differently in the reviewed studies. Sanrey et al [12] included in their study patients with early-to-moderate HD according to the disease stages defined by Shoulson and Fahn, which corresponds to grades I-III in this classification. In the study by Gonzalez et al [11], one inclusion criterion was a Total Functional Capacity (TFC) score ≤ 8, which corresponds to stage II or higher according to Shoulson and Fahn.…”

Section: Patient Qualificationmentioning

confidence: 99%

“…In only two studies was the presence of a reliable caregiver among the inclusion criteria [11,12]. Only one study reported the use of psychometric scales assessing some of the psychiatric symptoms [10], and no cut-offs were provided.…”

Section: Patient Qualificationmentioning

confidence: 99%

See 3 more Smart Citations

Is deep brain stimulation effective in Huntington’s Disease? — a systematic literature review

Kaczyńska

Sitek

Witkowski

et al. 2022

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Introduction. Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder. Substantial for a diagnosis of the disease are motor disorders, with chorea as a hallmark symptom. Other disease manifestations include cognitive dysfunction and psychiatric disorders. Currently, pharmacological treatment plays the most important role in the therapy of HD patients. However, deep brain stimulation (DBS) is considered a potential therapeutic option.Aim of the study. Systematic review of current literature on DBS efficacy and safety in the management of motor, behavioural and cognitive functions in patients with HD. Material and methods.A systematic review was conducted with the use of the Scopus database and the following search criteria: TITLE (huntington*) AND TITLE-ABS-KEY ('deep brain stimulation' OR 'neuromodulation'). Our search criteria included original studies with at least five patients, reporting any motor, cognitive and/or behavioural, and functional assessment data with at least a 6-month follow-up. Finally, four selected publications were analysed.Results. In all analysed publications, we found a statistically significant improvement of Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore by an average of 40, to over 60% after DBS implantation. Heterogeneous results were obtained for UHDRS total motor score. DBS did not improve functional capacity of HD patients in the analysed studies. We found no systematic assessment concerning the effect of DBS in HD on behaviour, cognition or speech.Conclusions. DBS implantation could be considered as a therapeutic option for patients with severe, drug-resistant chorea. However, the evidence for this is limited. To date, no high-quality data based on randomised controlled trials supports the long-term safety and efficacy of DBS in HD. This treatment option should therefore currently be considered as investigational.

show abstract

Section: Long-term Motor and Functional Outcomes Of Dbsmentioning

confidence: 97%

Section: Paper Selectionmentioning

confidence: 99%

Section: Patient Qualificationmentioning

confidence: 99%

Section: Patient Qualificationmentioning

confidence: 99%

See 2 more Smart Citations

Is deep brain stimulation effective in Huntington’s Disease? — a systematic literature review

Kaczyńska

Sitek

Witkowski

et al. 2022

Neurol Neurochir Pol.

View full text Add to dashboard Cite

show abstract

“…Global cognitive pro ile of HD subjects treated with CEN was stable during the irst 3 years of treatment. They also reported that chorea decreased post-operatively with a mean improvement of only 56% despite progession of the disease over time [118].…”

Section: Deep Brain Stimulationmentioning

confidence: 99%

Multimodal treatment strategies in Huntington’s disease

Dutta¹

2021

Neurosci Neurol Disord

View full text Add to dashboard Cite

Huntington’s disease (HD) is an incurable neurodegenerative disease that causes involuntary movements, emotional lability, and cognitive dysfunction. HD symptoms usually develop between ages 30 and 50, but can appear as early as 2 or as late as 80 years. Currently no neuroprotective and neurorestorative interventions are available. Early multimodal intervention in HD is only possible if the genetic diagnosis is made early. Early intervention in HD is only possible if genetic diagnosis is made at the disease onset or when mild symptoms manifest. Growing evidence and understanding of HD pathomechanism has led researchers to new therapeutic targets. Here, in this article we will talk about the multimodal treatment strategies and recent advances made in this field which can be used to target the HD pathogenesis at its most proximal level.

show abstract

Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington’s disease: an update

Kinfe

Vecchio

Nüssel

et al. 2022

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Does pallidal neuromodulation influence cognitive decline in Huntington’s disease?

Cited by 4 publications

References 52 publications

Is deep brain stimulation effective in Huntington’s Disease? — a systematic literature review

Is deep brain stimulation effective in Huntington’s Disease? — a systematic literature review

Multimodal treatment strategies in Huntington’s disease

Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington’s disease: an update

Contact Info

Product

Resources

About